An Ames-based biopharmaceutical company is laying off dozens of workers. Newlink Genetics announced Friday that 39 employees in its Ames office will be let go throughout the remainder of the year. CEO Charles Link says the layoffs come as the business focuses on the first round of clinical trials for two different forms of its Indoximod cancer treatment. The layoffs reflect half of its workforce. It comes after a tough summer for Newlink. It reported one of its treatment candidates for breast cancer patients failed to reach its primary outcome in phase two trials last month.